Latest Clinical Trials News

Page 15 of 140
Percheron Therapeutics has raised $2.3 million through an institutional placement to fully fund its upcoming acute myeloid leukemia clinical trial led by Vanderbilt Health.
Ada Torres
Ada Torres
1 Sept 2026
Racura Oncology has launched patient enrolment at its first Korean site for the CPACS Phase 1 trial, aiming to accelerate recruitment and validate RC220’s safety and efficacy in a key oncology market.
Ada Torres
Ada Torres
1 Sept 2026
Artrya has launched its AI-powered Salix® platform commercially in the US, securing three foundation health systems and raising $80 million to fuel growth. With FDA clearance for its Coronary Plaque module and a pivotal clinical study underway, the company is poised for scaling revenues amid a strong balance sheet.
Ada Torres
Ada Torres
1 Sept 2026
Optiscan Imaging has launched a 35-patient clinical trial in the US to test its InVue™ and InForm™ platforms in head and neck cancer surgery, aiming to bolster its FDA submissions later this year.
Ada Torres
Ada Torres
1 Sept 2026
Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.
Ada Torres
Ada Torres
31 Aug 2026
Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.
Ada Torres
Ada Torres
31 Aug 2026
Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.
Ada Torres
Ada Torres
31 Aug 2026
Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.
Ada Torres
Ada Torres
31 Aug 2026
Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.
Ada Torres
Ada Torres
31 Aug 2026
Alterity Therapeutics has arranged an underwriting deal for up to 8.4 million ATHO options, potentially raising A$4.2 million to A$7.96 million ahead of their expiry. The funds aim to support the upcoming Phase 3 trial for ATH434 in Multiple System Atrophy and bolster working capital.
Ada Torres
Ada Torres
31 Aug 2026
Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.
Ada Torres
Ada Torres
31 Aug 2026
EMVision has accelerated recruitment in its pivotal emu™ brain scanner trial, surpassing 200 patients and advancing FDA discussions to broaden clinical endpoints, setting the stage for regulatory submission in early 2027.
Ada Torres
Ada Torres
31 Aug 2026

Browse the archive

Full archive